Results of Multiple Sclerosis Drug Trail to be Presented at Neurology Annual Meeting

by Vishnuprasad on  April 10, 2015 at 12:49 AM Clinical Trials News
RSS Email Print This Page Comment
Font : A-A+

MedDay, a biotechnology company focused on the treatment of nervous system disorders, will present results of its pivotal clinical trial at The American Academy of Neurology (AAN) annual meeting in Washington DC, on April 24.
Results of Multiple Sclerosis Drug Trail to be Presented at Neurology Annual Meeting
Results of Multiple Sclerosis Drug Trail to be Presented at Neurology Annual Meeting

The trail investigates the efficacy and safety of MD1003 drug in the treatment of primary and secondary progressive multiple sclerosis (MS), a major area of unmet medical need.

MS-SPI is a randomized, double-blind, multi-center, placebo-controlled trial of MD1003, 300 mg/day, in patients with progressive MS.

A total of 154 patients with a baseline EDSS (Expanded Disability Status Scale) score of between 4.5 and 7 were enrolled from 16 MS reference centers across France. Treatment duration was one year.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Chemotherapy Chemotherapy Drugs Signature Drug Toxicity Infectious Mononucleosis Multiple Sclerosis Treatment and Modify Dandy Walker Syndrome Optic Neuritis Autoimmune Disorders Health Risks of Eating Pork 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive